-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Miltefosine-d9
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/miltefosine-d9.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | Miltefosine-d9 (HePC-d9) is the deuterium labeled Miltefosine. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT). |
Product Information
| Synonyms | Miltefosine-d9|HY-13685S|CS-0372468 |
| Molecular Weight | 416.62 |
| Molecular Formula | C21H46NO4P |
| Canonical SMILES | CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C |
| Melting Point | 232-234°C |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 363 |
| Exact Mass | 416.37293666 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| PSA | 68.40000 |
| Target | Akt; HIV |
| XLogP3-AA | 6.7 |
